Abstract
The use of haploidentical HSCT is gaining momentum using either megadose T-cell depleted (TCD) myeloablative HSCT, or T cell replete nonmyeloablative HSCT in conjunction with cyclophosphamide post-transplant (PTCY). However, the risks of myeloablative protocols in the former or prolonged immunosuppression in the later, adversely impacting GVL and anti-pathogen immunity are challenging. Recently, we demonstrated in a stringent BM allografting murine model, that combining megadose TCD HSCT with PTCY, enabled durable chimerism induction without GVHD in the absence of any immune suppression after CY. The outcome of this approach in onea patientwith multiple myeloma and one with Hodgkin's disease indicate it might offer an attractive safe protocol for haploidentical HSCT. In addition, preclinical experiments show that donor type anti-third party central memory veto T cells that are administrated with a megadose TCD HSCT can potentially offer an editional toolfor saferconditioning protocols. Moreover, proof of concept murine studies demonstrate that genetically manipulated veto cells armed with specific receptors against cancer cells, can survive for months in allogeneic recipients, laying the rational for the use of "off-the shelf " Veto-CAR T cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.